Vor Biopharma (VOR) Total Non-Current Liabilities (2024 - 2026)

Vor Biopharma (VOR) has reported Total Non-Current Liabilities for 3 consecutive years, with $18.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (changed N/A YoY), while the FY2025 annual figure was $27.9 million, down 39.67% from the prior year.
• Total Non-Current Liabilities declined to $18.7 million in Q1 2026 per VOR's latest filing, from $27.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $58.8 million in Q2 2025 and bottomed at $18.7 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $34.6 million across 3 years, with a median of $27.9 million in 2025.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 39.67% in 2025 and fell as far as 39.67% in 2025.
• Vor Biopharma's Total Non-Current Liabilities stood at $46.2 million in 2024, then tumbled by 39.67% to $27.9 million in 2025, then slumped by 32.92% to $18.7 million in 2026.
• Business Quant data shows VOR's Total Non-Current Liabilities at $18.7 million in Q1 2026, $27.9 million in Q4 2025, and $21.6 million in Q3 2025.